検索
EyePoint Pharmaceuticals Inc
EYPTウォッチリストに追加
4.250USD
+0.020+0.47%
終値 09-11 16:00（ET）
361.17M時価総額
損失額直近12ヶ月PER
詳細情報 EyePoint Pharmaceuticals Inc 企業名
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
EyePoint Pharmaceuticals Inc プロフィール
企業コードEYPT
会社名EyePoint Pharmaceuticals Inc
上場日Jan 27, 2005
最高経営責任者「CEO」Duker (Jay S)
従業員数165
証券種類Ordinary Share
決算期末Jan 27
本社所在地480 Pleasant Street, Suite C400
都市WATERTOWN
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号02472
電話番号16179265000
ウェブサイトhttps://eyepointpharma.com/
企業コードEYPT
上場日Jan 27, 2005
最高経営責任者「CEO」Duker (Jay S)
EyePoint Pharmaceuticals Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
952.69K
+0.90%
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
952.69K
+0.90%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
649.85K
-0.52%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Director
Non-Executive Director
182.86K
+21.87%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Director
Non-Executive Director
182.86K
+21.87%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
175.21K
+6.05%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
175.21K
+6.05%
Ms. Wendy F. DiCicco, CPA
Ms. Wendy F. DiCicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
137.46K
+21.85%
Ms. Wendy F. DiCicco, CPA
Ms. Wendy F. DiCicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
137.46K
+21.85%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
105.01K
+57.14%
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
952.69K
+0.90%
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
952.69K
+0.90%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
649.85K
-0.52%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Director
Non-Executive Director
182.86K
+21.87%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Director
Non-Executive Director
182.86K
+21.87%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
175.21K
+6.05%
よくある質問
EyePoint Pharmaceuticals Incの上位5名の株主は誰ですか？
EyePoint Pharmaceuticals Incの上位5名の株主は以下のとおりです。Dr. Jay S. Duker, M.D.
EyePoint Pharmaceuticals Inc（EYPT）の株式を保有している機関の数はいくつですか？
2026Q1時点で、EyePoint Pharmaceuticals Incの株式を保有している機関は381社あり、保有株式の総市場価値は約88.53Mで、全体の105.59%を占めています。2025Q4と比較して、機関の持ち株は-2754490.00増加しています。
EyePoint Pharmaceuticals Incの最大の収益源は何ですか？
2026Q1において、YUTIQ部門がEyePoint Pharmaceuticals Incにとって最大の収益を生み出しており、その金額は1.60Mで、全収益の5.10%を占めています。